Bright Minds Biosciences

Bright Minds Biosciences Inc. is a preclinical biotechnology firm dedicated to creating serotonin-based therapies. Its primary goal is to enhance the well-being of individuals suffering from severe and life-altering conditions. The company's development pipeline includes selective agonists for the 5-HT2C, 5-HT2A, and combined 5-HT2C/A serotonin receptors, which are being explored for potential treatments in epilepsy, pain management, and neuropsychiatric disorders. Bright Minds maintains strategic collaborations with the National Institutes of Health (NIH) for epilepsy research, the University of Texas Medical Branch (UTMB) for impulse control disorders like binge eating, and the Medical College of Wisconsin. The company, incorporated in 2019, operates from its headquarters in Vancouver, Canada.